|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Alexander_Zehnder
|
|
gptkbp:collaboratedWith
|
gptkb:Bayer
gptkb:GSK
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
|
|
gptkbp:country
|
gptkb:Germany
|
|
gptkbp:developedBy
|
gptkb:CVnCoV
|
|
gptkbp:focus
|
therapeutics
vaccine development
mRNA technology
|
|
gptkbp:founded
|
2000
|
|
gptkbp:foundedBy
|
gptkb:Florian_von_der_Mülbe
gptkb:Hans-Georg_Rammensee
gptkb:Ingmar_Hoerr
gptkb:Steve_Pascolo
Günther Jung
|
|
gptkbp:headquarters_location
|
gptkb:Tübingen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CureVac AG
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:languageOfWork
|
gptkb:German
English
|
|
gptkbp:notableProduct
|
CVnCoV COVID-19 vaccine candidate
|
|
gptkbp:numberOfEmployees
|
~600
|
|
gptkbp:parentOrganization
|
CureVac N.V.
|
|
gptkbp:researchArea
|
infectious diseases
oncology
rare diseases
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
2020
|
|
gptkbp:stockSymbol
|
gptkb:CVAC
|
|
gptkbp:website
|
https://www.curevac.com/
|
|
gptkbp:bfsParent
|
gptkb:CureVac_Real_Estate_GmbH
|
|
gptkbp:bfsLayer
|
8
|